BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:225Ac-ETN029 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of 225Ac-ETN029\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07006727-11272@assetmemo.bio
DTSTAMP:20261121T010441Z
DTSTART;VALUE=DATE:20310829
DTEND;VALUE=DATE:20310830
SUMMARY:225Ac-ETN029: Phase 1 readout est. (NCT07006727)
DESCRIPTION:225Ac-ETN029\, phase 1.\nStudy: Phase I Study of [225Ac]Ac-ETN0
 29 in Patients With Advanced DLL3-expressing Solid Tumors\nEstimated prima
 ry completion: 29 August 2031. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/225ac-etn029#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07006727
URL:https://assetmemo.bio/drug/225ac-etn029#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
